Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment.

Rushworth LK, Hewit K, Munnings-Tomes S, Somani S, James D, Shanks E, Dufès C, Straube A, Patel R, Leung HY.

Br J Cancer. 2019 Dec 17. doi: 10.1038/s41416-019-0681-5. [Epub ahead of print]

PMID:
31844184
2.

Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma.

Neidler S, Kruspig B, Hewit K, Monteverde T, Gyuraszova K, Braun A, Clark W, James D, Hedley A, Nieswandt B, Shanks E, Dick C, Murphy DJ.

Cancers (Basel). 2019 Apr 29;11(5). pii: E600. doi: 10.3390/cancers11050600.

3.

The phospholipid PI(3,4)P2 is an apical identity determinant.

Román-Fernández Á, Roignot J, Sandilands E, Nacke M, Mansour MA, McGarry L, Shanks E, Mostov KE, Bryant DM.

Nat Commun. 2018 Nov 28;9(1):5041. doi: 10.1038/s41467-018-07464-8.

4.

A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor.

Hewit K, Sandilands E, Martinez RS, James D, Leung HY, Bryant DM, Shanks E, Markert EK.

Cell Death Dis. 2018 Oct 19;9(11):1069. doi: 10.1038/s41419-018-1115-7.

5.

Harnessing synthetic lethality to predict the response to cancer treatment.

Lee JS, Das A, Jerby-Arnon L, Arafeh R, Auslander N, Davidson M, McGarry L, James D, Amzallag A, Park SG, Cheng K, Robinson W, Atias D, Stossel C, Buzhor E, Stein G, Waterfall JJ, Meltzer PS, Golan T, Hannenhalli S, Gottlieb E, Benes CH, Samuels Y, Shanks E, Ruppin E.

Nat Commun. 2018 Jun 29;9(1):2546. doi: 10.1038/s41467-018-04647-1.

6.

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.

Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, Hamilton G, Mukhopadhyay A, O'Prey J, Hair A, Melo JV, Chan E, Ryan KM, Maguer-Satta V, Druker BJ, Clark RE, Mitra S, Herzyk P, Nicolini FE, Salomoni P, Shanks E, Calabretta B, Holyoake TL, Helgason GV.

J Natl Cancer Inst. 2018 May 1;110(5):467-478. doi: 10.1093/jnci/djx236.

7.

The High-Affinity Interaction between ORC and DNA that Is Required for Replication Licensing Is Inhibited by 2-Arylquinolin-4-Amines.

Gardner NJ, Gillespie PJ, Carrington JT, Shanks EJ, McElroy SP, Haagensen EJ, Frearson JA, Woodland A, Blow JJ.

Cell Chem Biol. 2017 Aug 17;24(8):981-992.e4. doi: 10.1016/j.chembiol.2017.06.019. Epub 2017 Aug 3.

8.

3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes.

Davidson MA, Shanks EJ.

FEBS J. 2017 Sep;284(17):2705-2731. doi: 10.1111/febs.14061. Epub 2017 May 3. Review.

9.

Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments.

Peck B, Schug ZT, Zhang Q, Dankworth B, Jones DT, Smethurst E, Patel R, Mason S, Jiang M, Saunders R, Howell M, Mitter R, Spencer-Dene B, Stamp G, McGarry L, James D, Shanks E, Aboagye EO, Critchlow SE, Leung HY, Harris AL, Wakelam MJO, Gottlieb E, Schulze A.

Cancer Metab. 2016 Apr 1;4:6. doi: 10.1186/s40170-016-0146-8. eCollection 2016.

10.

LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation.

Mardilovich K, Baugh M, Crighton D, Kowalczyk D, Gabrielsen M, Munro J, Croft DR, Lourenco F, James D, Kalna G, McGarry L, Rath O, Shanks E, Garnett MJ, McDermott U, Brookfield J, Charles M, Hammonds T, Olson MF.

Oncotarget. 2015 Nov 17;6(36):38469-86. doi: 10.18632/oncotarget.6288.

11.

Academic drug discovery within the United Kingdom: a reassessment.

Shanks E, Ketteler R, Ebner D.

Nat Rev Drug Discov. 2015 Jul;14(7):510. doi: 10.1038/nrd4661. Epub 2015 Jun 19. No abstract available.

PMID:
26091271
12.

Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.

Miller BW, Morton JP, Pinese M, Saturno G, Jamieson NB, McGhee E, Timpson P, Leach J, McGarry L, Shanks E, Bailey P, Chang D, Oien K, Karim S, Au A, Steele C, Carter CR, McKay C, Anderson K, Evans TR, Marais R, Springer C, Biankin A, Erler JT, Sansom OJ.

EMBO Mol Med. 2015 Aug;7(8):1063-76. doi: 10.15252/emmm.201404827.

13.

Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress.

Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K, McGarry L, James D, Shanks E, Kalna G, Saunders RE, Jiang M, Howell M, Lassailly F, Thin MZ, Spencer-Dene B, Stamp G, van den Broek NJ, Mackay G, Bulusu V, Kamphorst JJ, Tardito S, Strachan D, Harris AL, Aboagye EO, Critchlow SE, Wakelam MJ, Schulze A, Gottlieb E.

Cancer Cell. 2015 Jan 12;27(1):57-71. doi: 10.1016/j.ccell.2014.12.002.

14.

Elevated LIM kinase 1 in nonmetastatic prostate cancer reflects its role in facilitating androgen receptor nuclear translocation.

Mardilovich K, Gabrielsen M, McGarry L, Orange C, Patel R, Shanks E, Edwards J, Olson MF.

Mol Cancer Ther. 2015 Jan;14(1):246-58. doi: 10.1158/1535-7163.MCT-14-0447. Epub 2014 Oct 24.

15.

Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality.

Jerby-Arnon L, Pfetzer N, Waldman YY, McGarry L, James D, Shanks E, Seashore-Ludlow B, Weinstock A, Geiger T, Clemons PA, Gottlieb E, Ruppin E.

Cell. 2014 Aug 28;158(5):1199-1209. doi: 10.1016/j.cell.2014.07.027.

16.

Strategic siRNA screening approaches to target cancer at the Cancer Research UK Beatson Institute.

Shanks EJ.

Comb Chem High Throughput Screen. 2014 May;17(4):328-32.

PMID:
24661213
17.

Dihydroquinazolines as a novel class of Trypanosoma brucei trypanothione reductase inhibitors: discovery, synthesis, and characterization of their binding mode by protein crystallography.

Patterson S, Alphey MS, Jones DC, Shanks EJ, Street IP, Frearson JA, Wyatt PG, Gilbert IH, Fairlamb AH.

J Med Chem. 2011 Oct 13;54(19):6514-30. doi: 10.1021/jm200312v. Epub 2011 Sep 1.

18.

Design, synthesis and biological evaluation of novel inhibitors of Trypanosoma brucei pteridine reductase 1.

Spinks D, Ong HB, Mpamhanga CP, Shanks EJ, Robinson DA, Collie IT, Read KD, Frearson JA, Wyatt PG, Brenk R, Fairlamb AH, Gilbert IH.

ChemMedChem. 2011 Feb 7;6(2):302-8. doi: 10.1002/cmdc.201000450. Epub 2010 Dec 29.

19.

Investigation of trypanothione reductase as a drug target in Trypanosoma brucei.

Spinks D, Shanks EJ, Cleghorn LA, McElroy S, Jones D, James D, Fairlamb AH, Frearson JA, Wyatt PG, Gilbert IH.

ChemMedChem. 2009 Dec;4(12):2060-9. doi: 10.1002/cmdc.200900262.

20.

Development and validation of a cytochrome c-coupled assay for pteridine reductase 1 and dihydrofolate reductase.

Shanks EJ, Ong HB, Robinson DA, Thompson S, Sienkiewicz N, Fairlamb AH, Frearson JA.

Anal Biochem. 2010 Jan 15;396(2):194-203. doi: 10.1016/j.ab.2009.09.003. Epub 2009 Sep 11.

Supplemental Content

Loading ...
Support Center